Get the app
US › Healthcare

LENZ Therapeutics Inc (LENZ)

US · Healthcare · Biotechnology

$3.27-8.40%
Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue
$5.5M
Revenue YoY
+9.7%
Net profit
$-31.9M
EPS
$-1.02
EPS estimate
$-1.21
Net margin
-581.8%

EPS came in at -1.02 against a street estimate of -1.21 — a beat of 15.7%.

Key statistics

Market cap
$106.8M
Forward P/E
0.0
P/B
0.54
Book value
$6.98
EPS (TTM)
$-3.89
52-week high
$42.98
52-week low
$3.35
50-day MA
$4.55
200-day MA
$8.94
Beta
1.73

Analyst view

Analysts rate LENZ Therapeutics Inc a buy (5 buy, 2 hold, 0 sell out of 7) with an average price target of $24.00.

Shareholding

Insiders
2.65%
Institutions
111.76%

Largest institutional holders

FundStake
RA Capital Management, LLC13.30%
Alpha Wave Global LP11.50%
FMR Inc11.33%
Versant Venture Management LLC8.46%
BlackRock Inc7.29%
Squarepoint Ops LLC5.56%
Aberdeen Group PLC4.93%
Millennium Management LLC4.80%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for LENZ Therapeutics Inc — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-10-18.